BioCellgraft - BioCellgraft specializes in regenerative health therapies specifically designed to enhance soft and hard tissue regeneration within the oral cavity. Our flagship product, OraFyl, is a highly purified biological matrix derived from the chorionic portion of the human placenta (HPCTM - Human Placenta Connective Tissue Matrix). It consists of native collagen and elastin presented in their most purified molecular scaffold form.
BioCellgraft specializes in regenerative health therapies specifically designed to enhance soft and hard tissue regeneration within the oral cavity. Our flagship product, OraFyl, is a highly purified biological matrix derived from the chorionic portion of the human placenta (HPCTM - Human Placenta Connective Tissue Matrix). It consists of native collagen and elastin presented in their most purified molecular scaffold form.
Michel Dard named “Biotech CEO of the Year (U.S.)” by Business Worldwide Magazine
BioCellgraft is proud to share that our CEO, Michel Dard, DDS, MS, PhD, has been named “Biotech CEO of the Year U.S. – Regenerative Dentistry and Oral Medicine” in Business Worldwide Magazine’s 2025 CEO Awards. PR Newswire
The annual program honors senior executives whose vision, strategy, and leadership drive innovation across industries. This year’s award recognizes Dr. Dard’s contributions to advancing biomaterial solutions for oral and craniofacial regeneration at BioCellgraft. PR Newswire
Source: Business Worldwide Magazine via PR Newswire; also carried by Yahoo Finance. PR Newswire+1
Read more: See the original award announcement and coverage. PR Newswire+1